Company Profile
DexCom, Inc. Stock Price, News & Catalysts
- Ticker:
- DXCM
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
86.23 USD (-0.07%)
Close
Last updated: October 1, 2026
28.3B USD
Market cap
Why the stock is moving
As of Oct 1, 2026, DXCM was little changed and closed at $86.23. No new same-company headline was identified in the current news window.
Company overview
Glucose Biosensing Company
Dexcom develops continuous glucose monitoring systems that help people measure and manage glucose without relying only on intermittent finger-stick tests. Its products serve people with diabetes as well as consumers seeking broader metabolic-health insights.
Prescription CGM Franchise
The Dexcom G7 platform provides real-time glucose readings, alerts, trend information, and connectivity to compatible mobile devices and insulin-delivery systems. The franchise is used across intensive insulin therapy, basal insulin, and expanding populations with type 2 diabetes.
Stelo Consumer Platform
Stelo is an over-the-counter glucose biosensor and app designed for adults who do not use insulin. It extends Dexcom into direct-to-consumer distribution and combines glucose data with food logging, behavioral insights, and AI-enabled interpretation.
Clinical Evidence and Market Expansion
Dexcom invests in randomized studies such as CONNECT to demonstrate the value of continuous glucose monitoring in less intensively treated populations. Evidence generation supports payer coverage, clinical guidelines, and adoption among primary-care clinicians and people with type 2 diabetes.
Connected Diabetes Ecosystem
The company integrates its sensors with insulin pumps, connected pens, digital health applications, and clinical data platforms. These partnerships make Dexcom's data a core component of automated insulin delivery and remote diabetes management.
Future catalysts
Recent news
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of DexCom, Inc. (DXCM)?
DexCom, Inc. (DXCM) most recently closed at 86.23 USD, a -0.07% move versus the previous session.
What is the market cap of DexCom, Inc. (DXCM)?
DexCom, Inc. currently has a market capitalization of 28.3B USD on BioPharmSignal.
What does DexCom, Inc. do?
Glucose Biosensing Company Dexcom develops continuous glucose monitoring systems that help people measure and manage glucose without relying only on intermittent finger-stick tests. Its products serve people with diabetes as well as consumers seeking broader metabolic-health insights. Prescription CGM Franchise The Dexcom G7 platform provides real-time...
On which exchange is DXCM stock listed?
DexCom, Inc. (DXCM) is associated with NASDAQ, United States, Biopharma.
What is Glucose?
Glucose Biosensing Company Dexcom develops continuous glucose monitoring systems that help people measure and manage glucose without relying only on intermittent finger-stick tests.
Which conditions is DexCom, Inc. targeting with Glucose?
DexCom, Inc. is associated with metabolic disease, diabetes based on its company overview and current catalyst commentary.
What is Biosensing?
Glucose Biosensing Company Dexcom develops continuous glucose monitoring systems that help people measure and manage glucose without relying only on intermittent finger-stick tests.
What is Dexcom?
Glucose Biosensing Company Dexcom develops continuous glucose monitoring systems that help people measure and manage glucose without relying only on intermittent finger-stick tests.